Predict your next investment

Venture Capital
biomed-venture.de

See what CB Insights has to offer

Investments

5

Portfolio Exits

4

Funds

1

About BioMed Venture

Investor focusing on life science companies.

BioMed Venture Headquarter Location

Breite Strasse 6 - 8

Hannover, 30159,

Germany

49 5113539650

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BioMed Venture News

List23: Latest U.S. News & Breaking World News Fauna Bio raises $9 million to expand the Comparative Genomics Platform for Novel Target Discovery by Expanding Comparativ Genome Discovery Platform

Sep 21, 2021

Sept. 21, 2021 /PRNewswire/ -- EMERYVILLE, Calif., Sept 21st 2022 -- Fauna Bio is a bio-based company that specializes in the development of Faunes. True Ventures, Boom Capital, Pacific 8 VentureS, BioMed Venture, Vibe Capital and Arcadia Science have partnered with LifeForce Capital to raise $9 million in Seed funding. Fauna Bio will utilize the new funds to expand its drug discovery platform Convergence while also accelerating the development of new therapeutic targets for human diseases across a broad range of indications. Fauna Bio exploits the power of comparative and functional genomics to provide better human disease treatments, such as neurologic, metabolic, fibrotic, and cardiovascular diseases, in order to identify better therapies for human diseases. The first version of Convergence examines gene expression data from hibernating mammals due to their extreme biology and their remarkable ability to reverse disease-causing traits. The platform has identified two compounds and four novel genetic targets currently under investigation for heart disease and related disorders, according to the platform. The firm works with Novo Nordisk on a target obesity discovery program. Fauna Bio has identified seven new genetic targets to reduce fibrosis, which is a key component of many chronic and debilitating diseases, including NASH and cardiovascular disease secondary to chronic kidney disease and diabetic cardiomyopathy. "Studying human biology and genetics alone has left us with many unanswered questions, gaps in knowledge, and without treatment to many serious diseases that could be assisted by looking outside our own species," said Ashley Zehnder, DVM, Ph.D., CEO of Fauna Bio. "After millions of years of evolution, animals have developed methods to naturally resist and heal from a variety of diseases that still plague humans. To improve health and wellness and, ultimately, longevity in humans, we are using these natural synergies between us and other mammals to help us maintain longevity." Bryan Burkey, Ph.D., has joined Fauna Bio as the Head of Therapeutics Discovery as it prepares for its internal pipeline toward clinical testing. Dr. Burkey is an experienced drug discovery and development professional who has led and contributed to a variety of activities, from target discovery to NDA filing. He led biology and translational pharmacology efforts for 23 years at Novartis Research, along with five years with Zafgen, Inc., and most recently was the Head of Systems Biology at Walden Biosciences. During his career, he developed knowledge in metabolic and cardiovascular pharmacology as well as safety assessment. Bryan excels in integrating information from in vitro target/pathway to in-vivo physiology/pharmacology to enable better drug development. The new investors in this funding round will leverage biotechnology and computational expertise to aid Fauna Bio's development and expansion into new disease areas. Lifeforce Capital invests in companies that are finding new ways to address the biggest healthcare problem, said John Noonan, LifeForce Capital's Managing Partner. "The all-female co-founding team at Fauna Bio demonstrates the cross-discipline collaboration the field of medicine needs to foster innovation and achieve real progress in finding new ways to treat serious diseases," she added. Fauna Bio is a biodiversity that is also active in the development of Faune Bio. Fauna Bio is developing new methods to treat human diseases such as cardiovascular, fibrotic, metabolic, and neurodegenerative diseases, by adopting mechanisms animals have developed for traits such causative hibernation and deep-diving. Fauna Bio is a consortium of three scientists with deep knowledge of the best science and resources in the field of non-model organisms. They collaborate to develop pre-clinical and early clinical testing for new therapeutics targeting human diseases. Visit www.faunabio.com to learn more about Faunana Bio. LifeForce Capital is a company that specializes in lifeForces Capital. Lifeforce Capital is a venture capital firm investing in healthcare's most slick software-driven businesses. We work with teams to improve care delivery at scale or enable significantly more efficient therapeutic development through computational biology, which can result in significant increase in efficiency. We establish close relationships with exceptional founding teams and provide sustained support as businesses expand, bringing to bear our deep healthcare investment, policy, clinical, and operational experience. Visit lifeforcecap.com or send an email to [email protected]. SOURCE Fauna Bio SURCE

BioMed Venture Investments

5 Investments

BioMed Venture has made 5 investments. Their latest investment was in *Acri.Tec as part of their Growth Equity on February 2, 2002.

CBI Logo

BioMed Venture Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/15/2002

Growth Equity

*Acri.Tec

$2.61M

Yes

1

1/15/2002

Seed

Subscribe to see more

$99M

Subscribe to see more

10

12/1/2001

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/1/2001

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/1/1998

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/15/2002

1/15/2002

12/1/2001

10/1/2001

4/1/1998

Round

Growth Equity

Seed

Series A

Series A

Seed

Company

*Acri.Tec

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.61M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

BioMed Venture Portfolio Exits

4 Portfolio Exits

BioMed Venture has 4 portfolio exits. Their latest portfolio exit was Cranium Telemetrics on October 31, 2007.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/31/2007

Acquired

Undisclosed Angel Investors

1

10/2/2007

Acquired

Subscribe to see more

Subscribe to see more

10

9/1/2006

Acquired

Subscribe to see more

Subscribe to see more

10

2/1/2006

Acquired

Subscribe to see more

Subscribe to see more

10

Date

10/31/2007

10/2/2007

9/1/2006

2/1/2006

Exit

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Undisclosed Angel Investors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

BioMed Venture Fund History

1 Fund History

BioMed Venture has 1 fund, including BioMed Venture.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/1/2000

BioMed Venture

Early-Stage Venture Capital

Closed

$23.46M

1

Closing Date

7/1/2000

Fund

BioMed Venture

Fund Type

Early-Stage Venture Capital

Status

Closed

Amount

$23.46M

Sources

1

BioMed Venture Team

5 Team Members

BioMed Venture has 5 team members, including former Chief Executive Officer, Axel Bruemmer.

Name

Work History

Title

Status

Axel Bruemmer

Chief Executive Officer

Former

Uwe Hofmann

Chief Executive Officer

Former

Willi Weddrin

Chief Executive Officer

Former

Frank Algermissen

Controller

Former

Axel Deuring

Managing Director

Former

Name

Axel Bruemmer

Uwe Hofmann

Willi Weddrin

Frank Algermissen

Axel Deuring

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Controller

Managing Director

Status

Former

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.